All News

2019

May

Media Release / May 07, 2019

New AveXis data at AAN showed long-term durability of Zolgensma® in patients with spinal muscular atrophy (SMA) Type 1

Read More
Media Release / May 07, 2019

Novartis presents first-of-its-kind algorithm-based tool to help MS patients and physicians evaluate and discuss early signs of progression to secondary progressive MS

Read More
Media Release / May 05, 2019

AveXis presented robust data at AAN demonstrating efficacy of Zolgensma® in broad spectrum of spinal muscular atrophy (SMA) patients

Read More
Media Release / May 02, 2019

Novartis to highlight extensive long-term safety and efficacy data of Aimovig® across the spectrum of migraine at AAN

Read More

April

Media Release / Apr 30, 2019

New data at AAN reinforce Novartis commitment to transforming the lives of people of all ages who live with neurological conditions

Read More
Media Release / Apr 30, 2019

Sandoz enters agreement for proposed trastuzumab biosimilar, currently in Phase III development, to treat selected HER2-positive cancer tumors

Read More
Child receiving child-friendly antimalarial in Kibera, Kenya.
Featured News / Apr 25, 2019

World Malaria Day 2019

Novartis reaffirms commitment to fighting malaria and recognizes the dedication of our people and partners.

Read More
A mother and her child sit under their new insecticide-treated net in Prongyeang, Kanthout commune, Cambodia
Story / Apr 24, 2019

Asian health experts call for final push to wipe out deadliest form of malaria

The most lethal strain could be eliminated by 2030, but major hurdles remain.

Read More
Trees casting shadows along Fabrikstrasse
Featured News / Apr 24, 2019

Novartis Financial Results – Q1 2019

Novartis announced the company’s financial results for the first quarter of 2019.

Read More
Media Release / Apr 24, 2019

Novartis starts 2019 with strong sales and double digit core[1] operating income growth, Mayzent launch and Alcon spin-off; profit guidance upgraded

Read More

Pages

Related Links

Novartis Annual Reporting Suite

Read and download the Annual Review, the Annual Report and Form 20-F, and the Novartis in Society report.

Learn More